Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-23936
Kurzwelly, D; Glas, M; Roth, P; Weimann, E; Lohner, H; Waha, A; Schabet, M; Reifenberger, G; Weller, M; Herrlinger, U (2010). Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 97(3):389-392.
This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62-90 years old), the complete response rate was 47%, median progression-free survival was 5 months, and median overall survival was 21 months. Five of 17 patients (29.4%) had prolonged responses for at least 12 months and survived for more than 24 months. Three of these patients had a methylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter, while the MGMT status was not assessable in the remaining two patients. Temozolomide monotherapy appears to be effective in a subgroup of elderly PCNSL patients and deserves further evaluation.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|DDC:||610 Medicine & health|
|Deposited On:||12 Nov 2009 10:32|
|Last Modified:||27 Nov 2013 18:32|
|Additional Information:||The original publication is available at www.springerlink.com|
|Citations:||Web of Science®. Times cited: 13|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page